These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 18544677

  • 1. Targeting a single mismatched minor histocompatibility antigen with tumor-restricted expression eradicates human solid tumors.
    Hambach L, Vermeij M, Buser A, Aghai Z, van der Kwast T, Goulmy E.
    Blood; 2008 Sep 01; 112(5):1844-52. PubMed ID: 18544677
    [Abstract] [Full Text] [Related]

  • 2. Possible role of minor h antigens in the persistence of donor chimerism after stem cell transplantation; relevance for sustained leukemia remission.
    van der Torren CR, van Hensbergen Y, Luther S, Aghai Z, Rychnavská ZS, Slot M, Scherjon S, Kröger N, Ganser A, Weissinger EM, Goulmy E, Hambach L.
    PLoS One; 2015 Sep 01; 10(3):e0119595. PubMed ID: 25774796
    [Abstract] [Full Text] [Related]

  • 3. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens.
    Dickinson AM, Wang XN, Sviland L, Vyth-Dreese FA, Jackson GH, Schumacher TN, Haanen JB, Mutis T, Goulmy E.
    Nat Med; 2002 Apr 01; 8(4):410-4. PubMed ID: 11927949
    [Abstract] [Full Text] [Related]

  • 4. Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy.
    Hambach L, Ling KW, Pool J, Aghai Z, Blokland E, Tanke HJ, Bruijn JA, Halfwerk H, van Boven H, Wieles B, Goulmy E.
    Blood; 2009 Mar 19; 113(12):2715-22. PubMed ID: 19096014
    [Abstract] [Full Text] [Related]

  • 5. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens.
    Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E.
    Blood; 1999 Apr 01; 93(7):2336-41. PubMed ID: 10090944
    [Abstract] [Full Text] [Related]

  • 6. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease.
    Mutis T, Gillespie G, Schrama E, Falkenburg JH, Moss P, Goulmy E.
    Nat Med; 1999 Jul 01; 5(7):839-42. PubMed ID: 10395333
    [Abstract] [Full Text] [Related]

  • 7. The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells.
    Klein CA, Wilke M, Pool J, Vermeulen C, Blokland E, Burghart E, Krostina S, Wendler N, Passlick B, Riethmüeller G, Goulmy E.
    J Exp Med; 2002 Aug 05; 196(3):359-68. PubMed ID: 12163564
    [Abstract] [Full Text] [Related]

  • 8. Analysis of immunodominance among minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation.
    Mori S, El-Baki H, Mullen CA.
    Bone Marrow Transplant; 2003 May 05; 31(10):865-75. PubMed ID: 12748663
    [Abstract] [Full Text] [Related]

  • 9. [Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation].
    Hudecek M, Bartsch K, Tschiedel S, Niederwieser D.
    Dtsch Med Wochenschr; 2008 Jul 05; 133(28-29):1511-6. PubMed ID: 18597211
    [Abstract] [Full Text] [Related]

  • 10. Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1.
    Oostvogels R, Minnema MC, van Elk M, Spaapen RM, te Raa GD, Giovannone B, Buijs A, van Baarle D, Kater AP, Griffioen M, Spierings E, Lokhorst HM, Mutis T.
    Leukemia; 2013 Mar 05; 27(3):642-9. PubMed ID: 23079962
    [Abstract] [Full Text] [Related]

  • 11. Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation.
    Mutis T, Blokland E, Kester M, Schrama E, Goulmy E.
    Blood; 2002 Jul 15; 100(2):547-52. PubMed ID: 12091347
    [Abstract] [Full Text] [Related]

  • 12. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
    Anderson LD, Mori S, Mann S, Savary CA, Mullen CA.
    Cancer Res; 2000 Oct 15; 60(20):5797-802. PubMed ID: 11059776
    [Abstract] [Full Text] [Related]

  • 13. Targeting haematopoietic-specific minor histocompatibility antigens to distinguish graft-versus-tumour effects from graft-versus-host disease.
    Spaapen R, Mutis T.
    Best Pract Res Clin Haematol; 2008 Sep 15; 21(3):543-57. PubMed ID: 18790454
    [Abstract] [Full Text] [Related]

  • 14. HA-1 and the SMCY-derived peptide FIDSYICQV (H-Y) are immunodominant minor histocompatibility antigens after bone marrow transplantation.
    Rufer N, Wolpert E, Helg C, Tiercy JM, Gratwohl A, Chapuis B, Jeannet M, Goulmy E, Roosnek E.
    Transplantation; 1998 Oct 15; 66(7):910-6. PubMed ID: 9798702
    [Abstract] [Full Text] [Related]

  • 15. Aberrant expression of BCL2A1-restricted minor histocompatibility antigens in melanoma cells: application for allogeneic transplantation.
    Torikai H, Akatsuka Y, Yatabe Y, Morishima Y, Kodera Y, Kuzushima K, Takahashi T.
    Int J Hematol; 2008 Jun 15; 87(5):467-473. PubMed ID: 18414982
    [Abstract] [Full Text] [Related]

  • 16. Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy.
    Goulmy E.
    Cancer J; 2004 Jun 15; 10(1):1-7. PubMed ID: 15000488
    [Abstract] [Full Text] [Related]

  • 17. HLA class I-minor histocompatibility antigen tetramers select cytotoxic T cells with high avidity to the natural ligand.
    Gillespie G, Mutis T, Schrama E, Kamp J, Esendam B, Falkenburg JF, Goulmy E, Moss P.
    Hematol J; 2000 Jun 15; 1(6):403-10. PubMed ID: 11920221
    [Abstract] [Full Text] [Related]

  • 18. TAP-inhibiting proteins US6, ICP47 and UL49.5 differentially affect minor and major histocompatibility antigen-specific recognition by cytotoxic T lymphocytes.
    Oosten LE, Koppers-Lalic D, Blokland E, Mulder A, Ressing ME, Mutis T, van Halteren AG, Wiertz EJ, Goulmy E.
    Int Immunol; 2007 Sep 15; 19(9):1115-22. PubMed ID: 17855435
    [Abstract] [Full Text] [Related]

  • 19. Exogenous Addition of Minor H Antigen HA-1+ Dendritic Cells to Skin Tissues Ex Vivo Causes Infiltration and Activation of HA-1-Specific Cytotoxic T Cells.
    Kim YH, Vyth-Dreese FA, Schrama E, Pavel S, Bajema I, Goulmy E, Spierings E.
    Biol Blood Marrow Transplant; 2011 Jan 15; 17(1):69-77. PubMed ID: 20708701
    [Abstract] [Full Text] [Related]

  • 20. Minor histocompatibility antigens as targets for immunotherapy using allogeneic immune reactions.
    Akatsuka Y, Morishima Y, Kuzushima K, Kodera Y, Takahashi T.
    Cancer Sci; 2007 Aug 15; 98(8):1139-46. PubMed ID: 17521316
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.